Background COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has hit the central China city of Wuhan since December 2019, which is highly contagious and transmitted by droplets (through cough and sneezing) and contacts. After a series of effective measures have been carried out in China, the pandemic has been reported to be aggressively contained, while more countries and regions across the world are being overwhelmed by the crisis with mounting cases. As COVID-19 is still quickly spreading globally, clinical analyses for more clinical cases are in urgent need to better understand the infection. In this study, 146 cases of COVID-19 in Guizhou province were followed up, their clinical characteristics were summarized, and therapeutic efficacy was evaluated.
Case presentation Clinical data of COVID-19 patients who were already discharged through April 15, 2020 were collected to summarize their basic conditions and evaluate therapeutic efficacy. Treatment strategies for 4 typical cases were retrospectively analyzed. Young adults were predominant cases of COVID-19 in Guizhou province. More than half of them had a clear history of recent travel to an epidemic area and family epidemic, featuring mild to moderate symptoms. The mortality was 1.4%, lower than the national average. Of the cases who met the discharge criteria, 13.9% relapsed after recovery. Chest CT images indicated that few cases had different degrees of the sequelae of lung injury induced by COVID-19. This could be a underlying relapse risk. The analysis of 4 cases showed that most of them had favorable prognosis.
Conclusion Most COVID-19 patients in Guizhou province are mild-to-moderate infections, with the mortality lower than the national average. However, the relapse rate after discharge is relatively high, with incomplete repair in the lung. Besides, the time window of ECMO and complications must be emphasized.